S. 2030: Advancing Targeted Therapies for Rare Diseases Act of 2016

A bill to allow the sponsor of an application for the approval of a targeted drug to rely upon data and information with respect to such sponsor's previously approved targeted drugs.

The bill’s titles are written by its sponsor.

What you can do

Overview

Introduced:

Sep 15, 2015

Status:

Reported by Committee on Feb 9, 2016

The committees assigned to this bill sent it to the House or Senate as a whole for consideration on February 9, 2016.

Sponsor:

Michael Bennet

Senior Senator from Colorado

Democrat

Text:

Read Text »
Last Updated: Apr 5, 2016
Length: 10 pages

History

Sep 15, 2015
 
Introduced

This is the first step in the legislative process.

Feb 9, 2016
 
Reported by Committee

A committee has issued a report to the full chamber recommending that the bill be considered further. Only about 1 in 4 bills are reported out of committee.

 
Passed Senate

 
Passed House

 
Signed by the President

S. 2030 is a bill in the United States Congress.

A bill must be passed by both the House and Senate in identical form and then be signed by the President to become law.

How to cite this information.

We recommend the following MLA-formatted citation when using the information you see here in academic work:

“S. 2030 — 114th Congress: Advancing Targeted Therapies for Rare Diseases Act of 2016.” www.GovTrack.us. 2015. December 7, 2016 <https://www.govtrack.us/congress/bills/114/s2030>

Where is this information from?

GovTrack automatically collects legislative information from a variety of governmental and non-governmental sources. This page is sourced primarily from Congress.gov, the official portal of the United States Congress. Congress.gov is generally updated one day after events occur, and so legislative activity shown here may be one day behind. Data via the congress project.